search
Back to results

Innovative Technologies for the Treatment of Pulmonary and Heart Failure

Primary Purpose

Cardiogenic Shock, Ventricular Arrythmia, Cardiac Arrest With Successful Resuscitation

Status
Recruiting
Phase
Not Applicable
Locations
Kazakhstan
Study Type
Interventional
Intervention
HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
Sponsored by
National Research Center for Cardiac Surgery, Kazakhstan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiogenic Shock focused on measuring Anesthesiology, Cardiothoracic surgery, Nephrology, Perfusion, Efferentology

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients on an extracorporeal life support system with heart failure:

  • Implantation of intravenous ECMO
  • Hemodynamic support with vasopressors and/or tonics;
  • Procalcitonin level ≥ 1 ng/ml;
  • Invasive hemodynamic monitoring;
  • Written informed consent.

Patients on an extracorporeal life support system with pulmonary failure:

  • IV ECMO implantation
  • High levels of venous and arterial CO2 (CO2> 50 mmHg),
  • Low paO2, SvO2, SpO2.
  • Invasive hemodynamic monitoring;
  • Written informed consent.

    -Patients with left ventricular assistive device implantation:

  • LVAD implantation
  • Biventricular heart failure IV
  • INTERMACS I-III
  • Hemodynamic support with vasopressors and/or tonics;
  • Procalcitonin level ≥ 0.1 ng/ml;
  • Invasive hemodynamic monitoring;
  • Written informed consent.

    -Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest:

  • Hemodynamic support with vasopressors and/or tonics;
  • Bypass duration> 120 minutes
  • Hypothermia ≤ 25 0С
  • Circulatory arrest
  • Procalcitonin level ≥ 1 ng/ml;
  • Invasive hemodynamic monitoring;
  • Written informed consent.

Exclusion Criteria:

  • Patients on an extracorporeal life support system with heart failure:

    • Age less than 18 years old
    • Terminal hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study
  • Patients on an extracorporeal life support system with pulmonary failure:

    • Age less than 18 years old
    • Terminal hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study
  • Patients with left ventricular assistive device implantation:

    • Age less than 18 years old
    • Acute hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study
  • Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest:

    • Age less than 18 years old
    • Terminal hepatic or renal failure just before the procedure
    • Patient's written refusal to participate in the study

Sites / Locations

  • National Research Center For Cardiac SurgeryRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

Intervention team (1/1 group)

Intervention team (1/2 group)

Intervention team (1/3 group)

Intervention team (1/4 group)

Intervention team (2/1 groups)

Intervention team (2/2 groups)

Intervention team (2/3 groups)

Intervention team (2/4 groups)

Arm Description

An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure... (10 patients)

An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure (10 patients).

An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients).

An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients).

An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure. (10 patients)

An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure. (10 patients)

An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients)

An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients)

Outcomes

Primary Outcome Measures

Extracorporeal life support system with pulmonary and / or heart failure: Cytokine response
The level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor alpha-factor) before the start, 2 hours after the start of ECMO support, when ECMO is turned off, 24 hours after ECMO is turned off.
Extracorporeal life support system with pulmonary and / or heart failure: SOFA-Score
Sequential Organ Failure Assessment Score at 24, 48, 72 h (values from 6 to 24, where the higher values explain higher disease severity)
Extracorporeal life support system with pulmonary and / or heart failure
Doses of vasopressors and / or inotropes (µg / h / kg bodyweight)
Patients with left ventricular assist device implantation: Difference of Cytokine response
Level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor necrosis factor-alfa, procalcitonin)
Patients with left ventricular assist device implantation:vasopressors and / or inotropes
Doses of vasopressors and / or inotropes (µg / h / kg bodyweight)
Patients with left ventricular assist device implantation:Renal function
creatinine level
Patients with left ventricular assist device implantation:Lactate level
Lactate level
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of Cytokine response
Level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor necrosis factor-alfa, procalcitonin, C-reactive protein)
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: SOFA-Score
Sequential Organ Failure Assessment Score at 24, 48, 72 h (values from 6 to 24, where the higher values explain higher disease severity)
Extracorporeal life support system with pulmonary and / or heart failure:Difference of mean arterial pressure
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
Extracorporeal life support system with pulmonary and / or heart failure: Difference of CVP
Comparison of CVP at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
Extracorporeal life support system with pulmonary and / or heart failure: Serum lactate
Level of serum lactate at 24, 48, 72 h
Extracorporeal life support system with pulmonary and / or heart failure:Days on ventilator, vasopressor and renal replacement therapy
Total days on ventilator, vasopressor and renal replacement therapy within 30 days post-surgery will be assessed
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of mean arterial pressure
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of CVP
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Level of Serum lactate
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)

Secondary Outcome Measures

Extracorporeal life support system with pulmonary and / or heart failure:The level of C-reactive protein (CRP)
The level of C-reactive protein (CRP) before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation.
Extracorporeal life support system with pulmonary and / or heart failure: Level of leukocyte
Level of leukocyte cells in the bloodstream at 24, 48 hours
Extracorporeal life support system with pulmonary and / or heart failure:Application and dosage of vasopressors
Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery
Patients with left ventricular assist device implantation: The level of C-reactive protein (CRP)
The level of C-reactive protein (CRP) before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation
Patients with left ventricular assist device implantation: Application and dosage of vasopressors
Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: The level of C-reactive protein (CRP)
The level of C-reactive protein (CRP) before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.
For operations with prolonged artificial circulation, hypothermia and circulatory arrest:Leukocyte function
Leukocyte function: heterogeneity of the population of leukocyte cells in the bloodstream
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Application and dosage of vasopressors
Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery
Extracorporeal life support system with pulmonary and / or heart failure:The level of leukocytes
The level of leukocytes before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation
Extracorporeal life support system with pulmonary and / or heart failure:The level of procalcitonin
The level of procalcitonin before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation.
Extracorporeal life support system with pulmonary and / or heart failure:Application and dosage of inotropes
Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery
Patients with left ventricular assist device implantation: The level of leukocytes
The level of leukocytes before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation
Patients with left ventricular assist device implantation: The level of procalcitonin
The level of procalcitonin before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation
Patients with left ventricular assist device implantation: Application and dosage of inotropes
Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery
For operations with prolonged cardio pulmonary bypass, hypothermia and circulatory arrest: The level of leukocytes
The level of leukocytes before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.
For operations with prolonged cardiopulmonary bypass, hypothermia, and circulatory arrest: The level of procalcitonin
The level of procalcitonin before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.
For operations with prolonged cardiopulmonary bypass, hypothermia, and circulatory arrest: Application and dosage of inotropes
Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery

Full Information

First Posted
September 9, 2021
Last Updated
October 11, 2021
Sponsor
National Research Center for Cardiac Surgery, Kazakhstan
Collaborators
Ministry of Education and Science, Republic of Kazakhstan
search

1. Study Identification

Unique Protocol Identification Number
NCT05090930
Brief Title
Innovative Technologies for the Treatment of Pulmonary and Heart Failure
Official Title
Development of Innovative Technologies for the Treatment of Pulmonary and Heart Failure to Prolong Human's Life
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2021 (Actual)
Primary Completion Date
July 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Research Center for Cardiac Surgery, Kazakhstan
Collaborators
Ministry of Education and Science, Republic of Kazakhstan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the program. Formulation of new treatments for heart and pulmonary failure through using organ-replacing technologies. Formulation of a clinical protocol and implementation of treatment methods into clinical practice heart and pulmonary failure using organ-replacing technologies. New methods were created for rehabilitating the function of affected organs after implantation of the LVAD, a total artificial heart, an extracorporeal life-sustaining system will be of great importance, both for Kazakhstan and for states with similar problems of donor organ deficiency, will also improve the effectiveness of surgical treatment and reduce the level of complications and mortality of patients on the extracorporeal life-sustaining system and septic patients.
Detailed Description
Objectives of the program. Task 1. Assessment of the results of the use of extracorporeal life support systems in the treatment of pulmonary and/or heart failure. Subtask 1.1. Assessment of the restoration of organ function during extracorporeal life support systems using extracorporeal hemocorrection. Subtask 1.2. Assessment of the normalization of the body's immune response and restoration of organ function during extracorporeal life support systems using an extracorporeal cytokine adsorber. Task 2. Studying the restoration of organ function during implantation of the left ventricular assist device as an organ-replacing aid in heart failure. Subtask 2.1. Assessment of the restoration of organ function during implantation of the left ventricular assist device with the use of extracorporeal hemocorrection. Subtask 2.2. Assessment of the normalization of the body's immune response and restoration of organ function upon implantation of the left ventricular assist device using an extracorporeal cytokine adsorber. Task 3. Studying the restoration of organ function during the implantation of the total artificial heart as an organ-replacing aid in case of heart failure. Task 3.1. Assessment of normalization of organ function restoration during implantation of the total artificial heart with the use of extracorporeal hemocorrection. Task 4. Studying the restoration of organ function during operations in conditions of the long-term cardiopulmonary bypass. Task 4.1. Assessment of the restoration of organ function during operations with long-term cardiopulmonary bypass, hypothermia, and circulatory arrest, with the use of extra corporeal hemocorrection. Task 4.2. Assessment of the restoration of organ function during operations with long-term cardiopulmonary bypass, hypothermia, and circulatory arrest using an extracorporeal cytokine adsorber. Task 5. Improvement of the method of implantation of organ-replacing technologies to reduce complications in the treatment of heart and pulmonary failure. Study design. Study type: interventional (clinical study) Set of participants: 100 participants Distribution: randomized Interventional model: parallel Masking: no Primary Goal: Treatment

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiogenic Shock, Ventricular Arrythmia, Cardiac Arrest With Successful Resuscitation, Sepsis, Multiple Organ Failure, Pulmonary Failure, Decompensated Heart Failure, Acute Heart Failure
Keywords
Anesthesiology, Cardiothoracic surgery, Nephrology, Perfusion, Efferentology

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Intervention team # 1 using an extracorporeal hemoperfusion device Jafron (Zhuhai Jafron Biomedical, China) (50 patients) in subgroups: A (n = 10) - patients on extracorporeal life support systems with heart failure; B (n = 10) - patients on extracorporeal life support systems with pulmonary failure; C (n = 5) - patients with implantation of a left ventricular accessory device; D (n = 25) - during operations with prolonged artificial circulation, hypothermia and circulatory arrest. Intervention team # 2 using extracorporeal cytokine, CytoSorb (CytoSorbents Corporation, Monmouth Junction, NJ, USA) (50 patients) in subgroups: A (n = 10) - patients on extracorporeal life support systems in heart failure; B (n = 10) - patients on extracorporeal life support systems with pulmonary failure; C (n = 5) - patients with implantation of a left ventricular accessory device; D (n = 25) - during operations with prolonged artificial circulation, hypothermia and circulatory arrest.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention team (1/1 group)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure... (10 patients)
Arm Title
Intervention team (1/2 group)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure (10 patients).
Arm Title
Intervention team (1/3 group)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients).
Arm Title
Intervention team (1/4 group)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients).
Arm Title
Intervention team (2/1 groups)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for heart failure. (10 patients)
Arm Title
Intervention team (2/2 groups)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in the device of the extracorporeal life support system for pulmonary failure. (10 patients)
Arm Title
Intervention team (2/3 groups)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in patients before/during the implantation of a left ventricular accessory (5 patients)
Arm Title
Intervention team (2/4 groups)
Arm Type
Active Comparator
Arm Description
An extracorporeal hemoperfusion device will be installed in patients during operations with prolonged artificial circulation, hypothermia, and circulatory arrest. (25 patients)
Intervention Type
Device
Intervention Name(s)
HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
Intervention Description
HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection, which is based on the removal of cytokines from whole blood by sorption on a special hemoadsorbent due to the peculiarities of its porous structure and inner surface, which is indicated in conditions where cytokine levels are extremely elevated
Intervention Type
Device
Intervention Name(s)
CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
Intervention Description
CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber is a biocompatible polymer with high adsorption capacity, which is indicated in conditions where cytokine levels are extremely elevated
Primary Outcome Measure Information:
Title
Extracorporeal life support system with pulmonary and / or heart failure: Cytokine response
Description
The level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor alpha-factor) before the start, 2 hours after the start of ECMO support, when ECMO is turned off, 24 hours after ECMO is turned off.
Time Frame
24-48 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure: SOFA-Score
Description
Sequential Organ Failure Assessment Score at 24, 48, 72 h (values from 6 to 24, where the higher values explain higher disease severity)
Time Frame
24, 48, 72 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure
Description
Doses of vasopressors and / or inotropes (µg / h / kg bodyweight)
Time Frame
Time: first 72 hours
Title
Patients with left ventricular assist device implantation: Difference of Cytokine response
Description
Level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor necrosis factor-alfa, procalcitonin)
Time Frame
24-48 hours
Title
Patients with left ventricular assist device implantation:vasopressors and / or inotropes
Description
Doses of vasopressors and / or inotropes (µg / h / kg bodyweight)
Time Frame
first 72 hours
Title
Patients with left ventricular assist device implantation:Renal function
Description
creatinine level
Time Frame
first 72 hours
Title
Patients with left ventricular assist device implantation:Lactate level
Description
Lactate level
Time Frame
first 72 hours
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of Cytokine response
Description
Level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-8, IL-10, tumor necrosis factor-alfa, procalcitonin, C-reactive protein)
Time Frame
24-48 hours
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: SOFA-Score
Description
Sequential Organ Failure Assessment Score at 24, 48, 72 h (values from 6 to 24, where the higher values explain higher disease severity)
Time Frame
24, 48, 72 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure:Difference of mean arterial pressure
Description
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
Time Frame
24, 48, 72 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure: Difference of CVP
Description
Comparison of CVP at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
Time Frame
24, 48, 72 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure: Serum lactate
Description
Level of serum lactate at 24, 48, 72 h
Time Frame
24, 48, 72 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure:Days on ventilator, vasopressor and renal replacement therapy
Description
Total days on ventilator, vasopressor and renal replacement therapy within 30 days post-surgery will be assessed
Time Frame
until day 30 post-surgery
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of mean arterial pressure
Description
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
Time Frame
24, 48, 72 hours
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Difference of CVP
Description
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
Time Frame
24, 48, 72 hours
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Level of Serum lactate
Description
Comparison of mean arterial pressure at 24, 48, 72 hours between between two interventions (CytoSorb and Jafron)
Time Frame
24, 48, 72 hours
Secondary Outcome Measure Information:
Title
Extracorporeal life support system with pulmonary and / or heart failure:The level of C-reactive protein (CRP)
Description
The level of C-reactive protein (CRP) before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation.
Time Frame
24-48 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure: Level of leukocyte
Description
Level of leukocyte cells in the bloodstream at 24, 48 hours
Time Frame
24-48 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure:Application and dosage of vasopressors
Description
Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery
Time Frame
first 48 hours
Title
Patients with left ventricular assist device implantation: The level of C-reactive protein (CRP)
Description
The level of C-reactive protein (CRP) before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation
Time Frame
24-48 hours
Title
Patients with left ventricular assist device implantation: Application and dosage of vasopressors
Description
Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery
Time Frame
first 48 hours
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: The level of C-reactive protein (CRP)
Description
The level of C-reactive protein (CRP) before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.
Time Frame
24-48 hours
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest:Leukocyte function
Description
Leukocyte function: heterogeneity of the population of leukocyte cells in the bloodstream
Time Frame
first 48 hours
Title
For operations with prolonged artificial circulation, hypothermia and circulatory arrest: Application and dosage of vasopressors
Description
Incidence of application and level of dosage of vasopressors on days 2 and 3 after surgery
Time Frame
first 48 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure:The level of leukocytes
Description
The level of leukocytes before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation
Time Frame
24-48 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure:The level of procalcitonin
Description
The level of procalcitonin before the start of ECMO, 2 hours after the implantation of ECMO, during ECMO, 24 hours after ECMO explantation.
Time Frame
24-48 hours
Title
Extracorporeal life support system with pulmonary and / or heart failure:Application and dosage of inotropes
Description
Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery
Time Frame
first 48 hours
Title
Patients with left ventricular assist device implantation: The level of leukocytes
Description
The level of leukocytes before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation
Time Frame
24-48 hours
Title
Patients with left ventricular assist device implantation: The level of procalcitonin
Description
The level of procalcitonin before the start of the operation, 2 hours after the start of the operation, when the operation is turned off, 24 hours after the shutdown of the operation
Time Frame
24-48 hours
Title
Patients with left ventricular assist device implantation: Application and dosage of inotropes
Description
Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery
Time Frame
first 48 hours
Title
For operations with prolonged cardio pulmonary bypass, hypothermia and circulatory arrest: The level of leukocytes
Description
The level of leukocytes before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.
Time Frame
24-48 hours
Title
For operations with prolonged cardiopulmonary bypass, hypothermia, and circulatory arrest: The level of procalcitonin
Description
The level of procalcitonin before the cardiopulmonary bypass 2 hours after the cardiopulmonary bypass, when the cardiopulmonary bypass is turned off, 24 hours after the cardiopulmonary bypass.
Time Frame
24-48 hours
Title
For operations with prolonged cardiopulmonary bypass, hypothermia, and circulatory arrest: Application and dosage of inotropes
Description
Incidence of application and level of dosage of inotropes on days 2 and 3 after surgery
Time Frame
first 48 hours
Other Pre-specified Outcome Measures:
Title
Length of stay
Description
Length of stay in the intensive care unit
Time Frame
first 48 hours
Title
Length of hospital stay
Description
Length of hospital stay
Time Frame
up to 1 month
Title
30 day survival rate.
Description
30 day survival rate.
Time Frame
30 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients on an extracorporeal life support system with heart failure: Implantation of intravenous ECMO Hemodynamic support with vasopressors and/or tonics; Procalcitonin level ≥ 1 ng/ml; Invasive hemodynamic monitoring; Written informed consent. Patients on an extracorporeal life support system with pulmonary failure: IV ECMO implantation High levels of venous and arterial CO2 (CO2> 50 mmHg), Low paO2, SvO2, SpO2. Invasive hemodynamic monitoring; Written informed consent. -Patients with left ventricular assistive device implantation: LVAD implantation Biventricular heart failure IV INTERMACS I-III Hemodynamic support with vasopressors and/or tonics; Procalcitonin level ≥ 0.1 ng/ml; Invasive hemodynamic monitoring; Written informed consent. -Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest: Hemodynamic support with vasopressors and/or tonics; Bypass duration> 120 minutes Hypothermia ≤ 25 0С Circulatory arrest Procalcitonin level ≥ 1 ng/ml; Invasive hemodynamic monitoring; Written informed consent. Exclusion Criteria: Patients on an extracorporeal life support system with heart failure: Age less than 18 years old Terminal hepatic or renal failure just before the procedure Patient's written refusal to participate in the study Patients on an extracorporeal life support system with pulmonary failure: Age less than 18 years old Terminal hepatic or renal failure just before the procedure Patient's written refusal to participate in the study Patients with left ventricular assistive device implantation: Age less than 18 years old Acute hepatic or renal failure just before the procedure Patient's written refusal to participate in the study Patients in operations with prolonged artificial circulation, hypothermia and circulatory arrest: Age less than 18 years old Terminal hepatic or renal failure just before the procedure Patient's written refusal to participate in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yuri Pya, PhD, MD
Phone
+77172272090
Email
rp.nrcsc@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Timur Lesbekov, MD
Phone
+77172703100
Email
lesbekovt@mail.ru
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yuri Pya, PhD, MD
Organizational Affiliation
National research Center for Cardiac Surgery JSC
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Research Center For Cardiac Surgery
City
Astana
ZIP/Postal Code
010000
Country
Kazakhstan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuriy Pya, PhD, MD
Phone
+77172703100
Email
rp.nrcsc@gmail.com
First Name & Middle Initial & Last Name & Degree
Zhuldyz Nurmykhametova, MD
Phone
+77781115377
Email
zhyzik-nur@mail.ru

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Yes: There is a plan to make IPD and related data dictionaries available.
IPD Sharing Time Frame
from October 2021 year and will become available till December 2023 year.
IPD Sharing Access Criteria
The resulting patient data will be strictly confidential with ensuring privacy through strictly limited access to data, de-identification of data and destruction after the end of the study.
IPD Sharing URL
http://heartcenter.kz
Citations:
PubMed Identifier
20413034
Citation
Starling RC. Improved quantity and quality of life: a winning combination to treat advanced heart failure. J Am Coll Cardiol. 2010 Apr 27;55(17):1835-6. doi: 10.1016/j.jacc.2010.03.010. No abstract available.
Results Reference
result
PubMed Identifier
22891167
Citation
Maciver J, Ross HJ. Quality of life and left ventricular assist device support. Circulation. 2012 Aug 14;126(7):866-74. doi: 10.1161/CIRCULATIONAHA.111.040279. No abstract available.
Results Reference
result
PubMed Identifier
26945160
Citation
Tozzi P, Hullin R. Mechanical circulatory support for destination therapy. Swiss Med Wkly. 2016 Mar 5;146:w14267. doi: 10.4414/smw.2016.14267. eCollection 2016.
Results Reference
result
PubMed Identifier
27836935
Citation
Paolone S. Extracorporeal Membrane Oxygenation (ECMO) for Lung Injury in Severe Acute Respiratory Distress Syndrome (ARDS): Review of the Literature. Clin Nurs Res. 2017 Dec;26(6):747-762. doi: 10.1177/1054773816677808. Epub 2016 Nov 11.
Results Reference
result
PubMed Identifier
29450594
Citation
Abrams D, Garan AR, Abdelbary A, Bacchetta M, Bartlett RH, Beck J, Belohlavek J, Chen YS, Fan E, Ferguson ND, Fowles JA, Fraser J, Gong M, Hassan IF, Hodgson C, Hou X, Hryniewicz K, Ichiba S, Jakobleff WA, Lorusso R, MacLaren G, McGuinness S, Mueller T, Park PK, Peek G, Pellegrino V, Price S, Rosenzweig EB, Sakamoto T, Salazar L, Schmidt M, Slutsky AS, Spaulding C, Takayama H, Takeda K, Vuylsteke A, Combes A, Brodie D; International ECMO Network (ECMONet) and The Extracorporeal Life Support Organization (ELSO). Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Med. 2018 Jun;44(6):717-729. doi: 10.1007/s00134-018-5064-5. Epub 2018 Feb 15.
Results Reference
result
PubMed Identifier
16855261
Citation
Hunt SA. Taking heart--cardiac transplantation past, present, and future. N Engl J Med. 2006 Jul 20;355(3):231-5. doi: 10.1056/NEJMp068048. No abstract available. Erratum In: N Engl J Med. 2006 Aug 31;355(9):967.
Results Reference
result
PubMed Identifier
18702960
Citation
Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008 Aug 19;52(8):587-98. doi: 10.1016/j.jacc.2008.05.020.
Results Reference
result
PubMed Identifier
25242124
Citation
Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J; International Society of Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first official adult heart transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 Oct;33(10):996-1008. doi: 10.1016/j.healun.2014.08.003. Epub 2014 Aug 14. No abstract available.
Results Reference
result
PubMed Identifier
18429658
Citation
Sogayar AM, Machado FR, Rea-Neto A, Dornas A, Grion CM, Lobo SM, Tura BR, Silva CL, Cal RG, Beer I, Michels V, Safi J, Kayath M, Silva E; Costs Study Group - Latin American Sepsis Institute. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics. 2008;26(5):425-34. doi: 10.2165/00019053-200826050-00006.
Results Reference
result
PubMed Identifier
26051981
Citation
Khwannimit B, Bhurayanontachai R. The direct costs of intensive care management and risk factors for financial burden of patients with severe sepsis and septic shock. J Crit Care. 2015 Oct;30(5):929-34. doi: 10.1016/j.jcrc.2015.05.011. Epub 2015 May 20.
Results Reference
result
PubMed Identifier
23899564
Citation
Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, Kurosawa S, Stepien D, Valentine C, Remick DG. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev. 2013 Jul;93(3):1247-88. doi: 10.1152/physrev.00037.2012.
Results Reference
result
PubMed Identifier
23544148
Citation
Kwan A, Hubank M, Rashid A, Klein N, Peters MJ. Transcriptional instability during evolving sepsis may limit biomarker based risk stratification. PLoS One. 2013;8(3):e60501. doi: 10.1371/journal.pone.0060501. Epub 2013 Mar 27.
Results Reference
result
PubMed Identifier
16497588
Citation
Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 Feb 24;124(4):783-801. doi: 10.1016/j.cell.2006.02.015.
Results Reference
result
PubMed Identifier
24232462
Citation
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013 Dec;13(12):862-74. doi: 10.1038/nri3552. Epub 2013 Nov 15.
Results Reference
result
PubMed Identifier
23725873
Citation
Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013 Aug;25(4):477-83. doi: 10.1016/j.coi.2013.05.006. Epub 2013 May 28.
Results Reference
result
PubMed Identifier
26258150
Citation
Laszlo I, Trasy D, Molnar Z, Fazakas J. Sepsis: From Pathophysiology to Individualized Patient Care. J Immunol Res. 2015;2015:510436. doi: 10.1155/2015/510436. Epub 2015 Jul 15.
Results Reference
result
PubMed Identifier
19531784
Citation
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856.
Results Reference
result
PubMed Identifier
11395904
Citation
Bellomo R, Baldwin I, Ronco C. Extracorporeal blood purification therapy for sepsis and systemic inflammation: its biological rationale. Contrib Nephrol. 2001;(132):367-74. doi: 10.1159/000060105.
Results Reference
result
PubMed Identifier
22751621
Citation
Namas RA, Namas R, Lagoa C, Barclay D, Mi Q, Zamora R, Peng Z, Wen X, Fedorchak MV, Valenti IE, Federspiel WJ, Kellum JA, Vodovotz Y. Hemoadsorption reprograms inflammation in experimental gram-negative septic peritonitis: insights from in vivo and in silico studies. Mol Med. 2012 Dec 20;18(1):1366-74. doi: 10.2119/molmed.2012.00106.
Results Reference
result
PubMed Identifier
18434884
Citation
Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008 May;36(5):1573-7. doi: 10.1097/CCM.0b013e318170b9a7.
Results Reference
result
PubMed Identifier
21918497
Citation
Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH, Wen XY, Rimmele T, Singbartl K, Federspiel WJ, Clermont G, Kellum JA. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012 Feb;81(4):363-9. doi: 10.1038/ki.2011.320. Epub 2011 Sep 14.
Results Reference
result
PubMed Identifier
18090355
Citation
Kellum JA, Venkataraman R, Powner D, Elder M, Hergenroeder G, Carter M. Feasibility study of cytokine removal by hemoadsorption in brain-dead humans. Crit Care Med. 2008 Jan;36(1):268-72. doi: 10.1097/01.CCM.0000291646.34815.BB.
Results Reference
result
PubMed Identifier
28871441
Citation
Friesecke S, Trager K, Schittek GA, Molnar Z, Bach F, Kogelmann K, Bogdanski R, Weyland A, Nierhaus A, Nestler F, Olboeter D, Tomescu D, Jacob D, Haake H, Grigoryev E, Nitsch M, Baumann A, Quintel M, Schott M, Kielstein JT, Meier-Hellmann A, Born F, Schumacher U, Singer M, Kellum J, Brunkhorst FM. International registry on the use of the CytoSorb(R) adsorber in ICU patients : Study protocol and preliminary results. Med Klin Intensivmed Notfmed. 2019 Nov;114(8):699-707. doi: 10.1007/s00063-017-0342-5. Epub 2017 Sep 4.
Results Reference
result
PubMed Identifier
28101605
Citation
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.
Results Reference
result
PubMed Identifier
10470572
Citation
Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. Intensive Care Med. 1999 Jul;25(7):686-96. doi: 10.1007/s001340050931.
Results Reference
result
PubMed Identifier
24811308
Citation
Hetz H, Berger R, Recknagel P, Steltzer H. Septic shock secondary to beta-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy. Int J Artif Organs. 2014 May;37(5):422-6. doi: 10.5301/ijao.5000315. Epub 2014 Apr 17.
Results Reference
result
PubMed Identifier
28343448
Citation
Kogelmann K, Jarczak D, Scheller M, Druner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017 Mar 27;21(1):74. doi: 10.1186/s13054-017-1662-9.
Results Reference
result
PubMed Identifier
28127437
Citation
David S, Thamm K, Schmidt BMW, Falk CS, Kielstein JT. Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care. 2017 Jan 21;5:12. doi: 10.1186/s40560-017-0208-1. eCollection 2017.
Results Reference
result
PubMed Identifier
29377282
Citation
Nemeth E, Kovacs E, Racz K, Soltesz A, Szigeti S, Kiss N, Csikos G, Koritsanszky KB, Berzsenyi V, Trembickij G, Fabry S, Prohaszka Z, Merkely B, Gal J. Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation-an observational study. Clin Transplant. 2018 Apr;32(4):e13211. doi: 10.1111/ctr.13211. Epub 2018 Feb 27. Erratum In: Clin Transplant. 2019 Jun;33(6):e13556. Abstract corrected.
Results Reference
result
PubMed Identifier
27288610
Citation
Trasy D, Tanczos K, Nemeth M, Hankovszky P, Lovas A, Mikor A, Laszlo I, Hajdu E, Osztroluczki A, Fazakas J, Molnar Z; EProK study group. Early procalcitonin kinetics and appropriateness of empirical antimicrobial therapy in critically ill patients: A prospective observational study. J Crit Care. 2016 Aug;34:50-5. doi: 10.1016/j.jcrc.2016.04.007. Epub 2016 Apr 13.
Results Reference
result
PubMed Identifier
22704255
Citation
Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn Microbiol Infect Dis. 2012 Jul;73(3):221-7. doi: 10.1016/j.diagmicrobio.2012.05.002.
Results Reference
result
PubMed Identifier
9635646
Citation
Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998 Jun;26(6):1001-6. doi: 10.1097/00003246-199806000-00015.
Results Reference
result
PubMed Identifier
29084247
Citation
Schadler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, Marx G, Putensen C, Spies C, Jorres A, Quintel M, Engel C, Kellum JA, Kuhlmann MK. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: A randomized controlled trial. PLoS One. 2017 Oct 30;12(10):e0187015. doi: 10.1371/journal.pone.0187015. eCollection 2017.
Results Reference
result
PubMed Identifier
28757818
Citation
Trasy D, Molnar Z. Procalcitonin - Assisted Antibiotic Strategy in Sepsis. EJIFCC. 2017 May 1;28(2):104-113. eCollection 2017 May.
Results Reference
result
PubMed Identifier
10890632
Citation
Tschaikowsky K, Sagner S, Lehnert N, Kaul M, Ritter J. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med. 2000 Jun;28(6):1854-60. doi: 10.1097/00003246-200006000-00028.
Results Reference
result
PubMed Identifier
29386200
Citation
Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. No abstract available. Erratum In: Circulation. 2018 Mar 20;137(12 ):e493.
Results Reference
result
PubMed Identifier
23519193
Citation
Rodriguez LE, Suarez EE, Loebe M, Bruckner BA. Ventricular assist devices (VAD) therapy: new technology, new hope? Methodist Debakey Cardiovasc J. 2013 Jan-Mar;9(1):32-7. doi: 10.14797/mdcj-9-1-32.
Results Reference
result
PubMed Identifier
17638928
Citation
Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007 Jul 31;116(5):497-505. doi: 10.1161/CIRCULATIONAHA.107.691972. Epub 2007 Jul 16.
Results Reference
result
PubMed Identifier
23352391
Citation
Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013 Feb;32(2):157-87. doi: 10.1016/j.healun.2012.09.013. No abstract available.
Results Reference
result
PubMed Identifier
23888228
Citation
Hetzer R, Delmo Walter EM. Trends and outcomes in heart transplantation: the Berlin experience. HSR Proc Intensive Care Cardiovasc Anesth. 2013;5(2):76-80.
Results Reference
result
PubMed Identifier
15276536
Citation
Chen YF, Tsai WC, Lin CC, Tsai LY, Lee CS, Huang CH, Pan PC, Chen ML. Effect of leukocyte depletion on endothelial cell activation and transendothelial migration of leukocytes during cardiopulmonary bypass. Ann Thorac Surg. 2004 Aug;78(2):634-42; discussion 642-3. doi: 10.1016/j.athoracsur.2004.02.091.
Results Reference
result

Learn more about this trial

Innovative Technologies for the Treatment of Pulmonary and Heart Failure

We'll reach out to this number within 24 hrs